Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Imeglimin shows promise in phase II trials in type 2 diabetes

Sep. 29, 2010

Phase II data on MK-0941 cast doubt on suitability for treatment of diabetes

Sep. 29, 2010

Namisol tablet for multiple sclerosis shows promise in first-in-human trial

Sep. 28, 2010

E-6005 improves pruritus and inflammation in preclinical tests

Sep. 28, 2010

NexMed and Bio-Quant present preclinical data on PrevOnco

Sep. 28, 2010

Phico Therapeutics details phase I tolerability of PT1.2

Sep. 27, 2010

BI-10773 improves glycemic control in large study in type 2 diabetes

Sep. 27, 2010

Novartis reports on clinical development of LDE-225

Sep. 27, 2010

Interim phase I/II data suggest safety of everolimus in advanced HCC

Sep. 27, 2010

Phase I data presented on hypnotic agent GF-015535-00

Sep. 27, 2010

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...